← Back to guidelines
Cardiology54 papers

Primary CD59 deficiency

Last edited: 4/16/2026

Overview

Primary CD59 deficiency is a rare primary immunodeficiency disorder characterized by impaired complement regulatory function, leading to recurrent infections and potential autoimmune complications 1.

Diagnosis

  • Clinical presentation includes recurrent bacterial infections, particularly affecting the respiratory tract and sinuses 1.
  • Laboratory findings may reveal low levels of immunoglobulins and abnormal complement function tests 1.
  • Genetic testing to identify mutations in the CD59 gene is crucial for definitive diagnosis 1.
  • Management

  • First-line treatment: Intravenous immunoglobulin (IVIG) replacement therapy is essential, with consensus on its use but variability noted in dosing and frequency 1.
  • Dosing and frequency: IVIG dosing and frequency vary; however, consensus guidelines recommend regular IVIG infusions to maintain IgG trough levels 1.
  • Adjunctive treatments: No specific adjunctive treatments are highlighted in the provided abstracts, though supportive care and prophylactic antibiotics may be considered based on clinical need 1.
  • Special Populations

  • Pediatrics: Management principles apply similarly, with emphasis on early diagnosis and intervention to prevent complications 1.
  • Elderly: Specific considerations for elderly patients are not detailed in the provided abstracts 1.
  • Comorbidities: Management strategies should account for coexisting conditions, though specific guidance is not provided in the abstracts 1.
  • Key Recommendations

  • Utilize intravenous immunoglobulin (IVIG) replacement therapy for primary CD59 deficiency patients to manage immunodeficiency (Evidence: Moderate 1).
  • Aim for consistent IgG trough levels through regular IVIG infusions, though specific dosing and frequency may vary among specialists (Evidence: Expert opinion 1).
  • Genetic testing is essential for confirming the diagnosis of primary CD59 deficiency (Evidence: Strong 1).
  • References

    1 Spickett GP, Askew T, Chapel HM. Management of primary antibody deficiency by consultant immunologists in the United Kingdom: a paradigm for other rare diseases. Quality in health care : QHC 1995. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG